KALA BIO (NASDAQ:KALA) CFO Mary Reumuth Sells 32,230 Shares of Stock

KALA BIO, Inc. (NASDAQ:KALA) CFO Mary Reumuth sold 32,230 shares of KALA BIO stock in a transaction that occurred on Wednesday, October 22nd. The shares were sold at an average price of $0.83, for a total value of $26,750.90. Following the completion of the sale, the chief financial officer owned 29,873 shares in the company, valued at approximately $24,794.59. This trade represents a 51.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Mary Reumuth also recently made the following trade(s):

• On Thursday, October 23rd, Mary Reumuth sold 967 shares of KALA BIO stock. The shares were sold at an average price of $0.82, for a total value of $792.94.

KALA BIO Price Performance

Shares of NASDAQ KALA opened at $0.80 on Friday. The company has a debt-to-equity ratio of 3.19, a quick ratio of 2.10 and a current ratio of 2.10. KALA BIO, Inc. has a one year low of $0.77 and a one year high of $20.60. The firm has a market capitalization of $5.59 million, a P/E ratio of -0.12 and a beta of -2.10. The company’s fifty day moving average is $9.01 and its two-hundred day moving average is $6.27.

KALA BIO (NASDAQ:KALA) last announced its quarterly earnings data on Friday, August 8th. The company reported ($1.71) EPS for the quarter, beating the consensus estimate of ($1.82) by $0.11. Analysts forecast that KALA BIO, Inc. will post -10.84 EPS for the current fiscal year.

Institutional Investors Weigh In On KALA BIO

Large investors have recently bought and sold shares of the stock. XTX Topco Ltd purchased a new position in KALA BIO during the second quarter worth $62,000. Geode Capital Management LLC lifted its position in shares of KALA BIO by 2.8% in the second quarter. Geode Capital Management LLC now owns 56,367 shares of the company’s stock valued at $268,000 after acquiring an additional 1,534 shares in the last quarter. AIGH Capital Management LLC boosted its stake in shares of KALA BIO by 52.8% during the second quarter. AIGH Capital Management LLC now owns 300,000 shares of the company’s stock valued at $1,428,000 after acquiring an additional 103,650 shares during the last quarter. Woodline Partners LP purchased a new stake in KALA BIO during the 1st quarter worth about $1,483,000. Finally, ADAR1 Capital Management LLC increased its position in KALA BIO by 35.7% during the 1st quarter. ADAR1 Capital Management LLC now owns 298,955 shares of the company’s stock worth $1,713,000 after purchasing an additional 78,582 shares in the last quarter. Institutional investors and hedge funds own 24.61% of the company’s stock.

Analyst Upgrades and Downgrades

KALA has been the topic of several research analyst reports. Mizuho set a $1.50 price target on KALA BIO in a research note on Tuesday, September 30th. Oppenheimer boosted their target price on KALA BIO from $15.00 to $33.00 and gave the stock an “outperform” rating in a research report on Thursday, September 11th. HC Wainwright reissued a “neutral” rating on shares of KALA BIO in a report on Monday, September 29th. Lifesci Capital cut KALA BIO from a “strong-buy” rating to a “hold” rating in a research report on Monday, September 29th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of KALA BIO in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, four have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $20.38.

About KALA BIO

KALA BIO, Inc, a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of innovative therapies for rare and severe eye diseases in the United States. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects.